Drug major Roche has reduced the prices of its Hepatitis C treatment drug 'Exxura' by 65 per cent across all government institutions in India.
After the price reduction, the medicine is now available at Rs 3,250 per pre-filled syringe plus taxes across all government institutions in the country, Roche said in a statement.
The move to reduce its cost of therapy is in line with Roche's commitment to treat patients with Hepatitis C, which continues to be a substantial disease burden in the northern states of India..., it added.
Exxura is available as a pre-filled syringe version to the patients, which offers dosing accuracy and convenience, the company said.
Commenting on the development, Director - Market Access for Roche India V Simpson Emmanuel said: "Roche is committed to working with the government and other stakeholders to control Hepatitis C infection..."
The company, quoting WHO, said 12 million people are chronically infected with Hepatitis C infection in India.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.